Abbott Laboratories Net Profit Margin 2010-2025 | ABT
Current and historical net profit margin for Abbott Laboratories (ABT) from 2010 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue. Abbott Laboratories net profit margin for the three months ending March 31, 2025 was .
| Abbott Laboratories Net Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Net Income | Net Margin |
| 2025-03-31 | $42.34B | $13.50B | 31.89% |
| 2024-12-31 | $41.95B | $13.40B | 31.95% |
| 2024-09-30 | $41.22B | $5.77B | 13.99% |
| 2024-06-30 | $40.73B | $5.56B | 13.65% |
| 2024-03-31 | $40.33B | $5.63B | 13.96% |
| 2023-12-31 | $40.11B | $5.72B | 14.27% |
| 2023-09-30 | $39.96B | $5.16B | 12.92% |
| 2023-06-30 | $40.23B | $5.16B | 12.83% |
| 2023-03-31 | $41.51B | $5.80B | 13.98% |
| 2022-12-31 | $43.65B | $6.93B | 15.88% |
| 2022-09-30 | $45.03B | $7.89B | 17.52% |
| 2022-06-30 | $45.55B | $8.55B | 18.78% |
| 2022-03-31 | $44.51B | $7.73B | 17.35% |
| 2021-12-31 | $43.08B | $7.07B | 16.42% |
| 2021-09-30 | $42.31B | $7.24B | 17.12% |
| 2021-06-30 | $40.23B | $6.38B | 15.85% |
| 2021-03-31 | $37.34B | $5.72B | 15.33% |
| 2020-12-31 | $34.61B | $4.50B | 12.99% |
| 2020-09-30 | $32.22B | $3.38B | 10.50% |
| 2020-06-30 | $31.44B | $3.11B | 9.89% |
| 2020-03-31 | $32.10B | $3.58B | 11.15% |
| 2019-12-31 | $31.90B | $3.69B | 11.56% |
| 2019-09-30 | $31.36B | $3.29B | 10.50% |
| 2019-06-30 | $30.94B | $2.90B | 9.36% |
| 2019-03-31 | $30.72B | $2.62B | 8.53% |
| 2018-12-31 | $30.58B | $2.37B | 7.74% |
| 2018-09-30 | $30.40B | $0.89B | 2.91% |
| 2018-06-30 | $29.58B | $0.93B | 3.13% |
| 2018-03-31 | $28.45B | $0.48B | 1.67% |
| 2017-12-31 | $27.39B | $0.48B | 1.74% |
| 2017-09-30 | $25.13B | $2.10B | 8.37% |
| 2017-06-30 | $23.61B | $1.17B | 4.96% |
| 2017-03-31 | $22.30B | $1.50B | 6.74% |
| 2016-12-31 | $20.85B | $1.40B | 6.71% |
| 2016-09-30 | $20.71B | $1.37B | 6.61% |
| 2016-06-30 | $20.56B | $2.28B | 11.08% |
| 2016-03-31 | $20.39B | $2.45B | 12.00% |
| 2015-12-31 | $20.41B | $4.42B | 21.68% |
| 2015-09-30 | $20.57B | $4.56B | 22.17% |
| 2015-06-30 | $20.50B | $4.52B | 22.04% |
| 2015-03-31 | $20.39B | $4.20B | 20.60% |
| 2014-12-31 | $20.25B | $2.28B | 11.28% |
| 2014-09-30 | $18.90B | $1.97B | 10.42% |
| 2014-06-30 | $18.65B | $2.40B | 12.86% |
| 2014-03-31 | $19.03B | $2.41B | 12.65% |
| 2013-12-31 | $19.66B | $2.58B | 13.10% |
| 2013-09-30 | $18.84B | $3.04B | 16.13% |
| 2013-06-30 | $19.28B | $4.02B | 20.83% |
| 2013-03-31 | $19.14B | $5.27B | 27.50% |
| 2012-12-31 | $19.05B | $5.96B | 31.30% |
| 2012-09-30 | $26.24B | $6.53B | 24.88% |
| 2012-06-30 | $30.79B | $4.89B | 15.88% |
| 2012-03-31 | $35.09B | $5.11B | 14.55% |
| 2011-12-31 | $38.85B | $4.73B | 12.17% |
| 2011-09-30 | $38.44B | $4.55B | 11.84% |
| 2011-06-30 | $37.30B | $5.14B | 13.78% |
| 2011-03-31 | $36.51B | $4.49B | 12.29% |
| 2010-12-31 | $35.17B | $4.63B | 13.16% |
| 2010-09-30 | $33.99B | $4.73B | 13.90% |
| 2010-06-30 | $33.08B | $5.31B | 16.07% |
| 2010-03-31 | $31.74B | $5.31B | 16.73% |
| 2009-12-31 | $30.76B | $5.75B | 18.68% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $231.503B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boston Scientific (BSX) | United States | $154.040B | 38.56 |
| Stryker (SYK) | United States | $144.095B | 30.13 |
| EssilorLuxottica (ESLOY) | France | $132.622B | 0.00 |
| Medtronic (MDT) | Ireland | $105.579B | 15.42 |
| Lonza Group Ag (LZAGY) | Switzerland | $51.866B | 0.00 |
| Haleon (HLN) | United Kingdom | $48.124B | 27.36 |
| ResMed (RMD) | United States | $35.477B | 26.65 |
| GE HealthCare Technologies (GEHC) | United States | $30.720B | 14.59 |
| Agilent Technologies (A) | United States | $30.004B | 19.82 |
| Terumo (TRUMY) | Japan | $29.197B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $22.643B | 16.28 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.255B | 11.72 |
| Insulet (PODD) | United States | $18.215B | 77.74 |
| Baxter (BAX) | United States | $15.352B | 11.47 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.456B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.032B | 0.00 |
| Demant (WILYY) | Denmark | $7.970B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $7.179B | 17.65 |
| Bio-Rad Laboratories (BIO) | United States | $6.487B | 21.93 |
| Prestige Consumer Healthcare (PBH) | United States | $4.014B | 19.16 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Perrigo (PRGO) | Ireland | $3.368B | 9.64 |
| ICU Medical (ICUI) | United States | $3.306B | 28.16 |
| Haemonetics (HAE) | United States | $3.194B | 15.03 |
| Envista Holdings (NVST) | United States | $2.778B | 23.08 |
| GN Store Nord (GNNDY) | Denmark | $2.069B | 17.14 |
| LeMaitre Vascular (LMAT) | United States | $1.855B | 41.46 |
| QuidelOrtho (QDEL) | United States | $1.750B | 14.65 |
| AtriCure (ATRC) | United States | $1.478B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.281B | 20.17 |
| AdaptHealth (AHCO) | United States | $1.194B | 12.12 |
| Neogen (NEOG) | United States | $1.192B | 15.25 |
| Kestra Medical Technologies (KMTS) | United States | $1.139B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.043B | 0.00 |
| InMode (INMD) | Israel | $0.995B | 9.11 |
| Phibro Animal Health (PAHC) | United States | $0.771B | 11.83 |
| Evolus (EOLS) | United States | $0.749B | 0.00 |
| Owens & Minor (OMI) | United States | $0.596B | 5.07 |
| Curaleaf Holdings (CURLF) | Canada | $0.579B | 0.00 |
| CeriBell (CBLL) | United States | $0.568B | 0.00 |
| Valneva SE (VALN) | France | $0.542B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.518B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.424B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.420B | 0.00 |
| Surmodics (SRDX) | United States | $0.391B | 0.00 |
| Omeros (OMER) | United States | $0.370B | 0.00 |
| SNDL (SNDL) | Canada | $0.344B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.340B | 14.75 |
| Capricor Therapeutics (CAPR) | United States | $0.333B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.302B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.292B | 26.43 |
| Sanara MedTech (SMTI) | United States | $0.283B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.262B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.259B | 46.10 |
| ZimVie (ZIMV) | United States | $0.245B | 14.65 |
| Cerus (CERS) | United States | $0.239B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.235B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.217B | 0.00 |
| Quanterix (QTRX) | United States | $0.208B | 0.00 |
| High Tide (HITI) | Canada | $0.192B | 0.00 |
| Biote (BTMD) | United States | $0.184B | 4.21 |
| Utah Medical Products (UTMD) | United States | $0.176B | 14.16 |
| TriSalus Life Sciences (TLSI) | United States | $0.166B | 0.00 |
| Brainsway (BWAY) | Israel | $0.162B | 50.65 |
| Organigram Global (OGI) | Canada | $0.147B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.146B | 17.99 |
| Jin Medical (ZJYL) | China | $0.130B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.117B | 0.00 |
| Exagen (XGN) | United States | $0.116B | 0.00 |
| Agape ATP (ATPC) | $0.103B | 0.00 | |
| MacroGenics (MGNX) | United States | $0.093B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.091B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.091B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.086B | 0.00 |
| Fonar (FONR) | United States | $0.076B | 10.58 |
| Veru (VERU) | United States | $0.074B | 0.00 |
| InterCure (INCR) | Israel | $0.073B | 0.00 |
| Zynex (ZYXI) | United States | $0.061B | 0.00 |
| United Health Products (UEEC) | United States | $0.059B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.056B | 0.00 |
| ImmuCell (ICCC) | United States | $0.046B | 0.00 |
| Modular Medical (MODD) | United States | $0.041B | 0.00 |
| Apyx Medical (APYX) | United States | $0.040B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.038B | 55.50 |
| Safety Shot (SHOT) | United States | $0.037B | 0.00 |
| United-Guardian (UG) | United States | $0.036B | 11.14 |
| Nephros (NEPH) | United States | $0.019B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.015B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.011B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.011B | 0.00 |
| Flora Growth (FLGC) | United States | $0.011B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.007B | 0.00 |
| Senestech (SNES) | United States | $0.004B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.004B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.004B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |